Related Experiment Video

Updated: Apr 25, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.3K

MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer

Mei-Yi Wu1, Junjiang Fu2, Xiuli Xiao3

  • 1Department of Biochemistry and Molecular Medicine, George Washington University, Washington, D.C. 20037, USA.

Cancer Letters
|September 1, 2014
PubMed

Insights

This study reveals how miR-34a targets HDAC1/HDAC7 to regulate HSP70 K246, inhibiting cancer cell survival and improving therapy response in breast cancer.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cancer Research

Background:

  • Therapy resistance in cancer leads to increased mortality and presents a significant clinical challenge.
  • The molecular mechanisms driving cancer therapy resistance are not fully understood.
  • MiR-34a, a tumor suppressor, is downregulated in cancer stem cells (CSCs), and its re-expression can inhibit tumor growth.

Purpose of the Study:

  • To elucidate the mechanism by which miR-34a regulates therapy resistance in breast cancer.
  • To identify novel targets of miR-34a involved in therapy resistance.
  • To explore the potential of targeting the identified pathway for new anti-cancer therapies.

Main Methods:

  • Identification of miR-34a targets using molecular biology techniques.
  • Investigation of the role of HDAC1, HDAC7, and HSP70 K246 in cancer cell survival and therapy resistance.
  • Analysis of the impact of the miR-34a-HDAC-HSP70 axis on autophagic cell death.

Main Results:

  • HDAC1 and HDAC7 were identified as novel targets of miR-34a in breast cancer.
  • Deacetylation of HSP70 K246 by HDAC1 and HDAC7 was found to promote cancer cell survival and therapy resistance.
  • This process was linked to the inhibition of autophagic cell death.

Conclusions:

  • The miR-34a-HDAC1/HDAC7-HSP70 K246 axis represents a novel molecular signature predictive of therapy resistance in breast cancer.
  • Targeting this axis offers a potential therapeutic strategy to overcome therapy resistance.
  • Understanding this mechanism is crucial for developing novel anti-cancer treatments.
Keywords:
DeacetylationHSP70Histone deacetylasemicroRNA

More Related Videos

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

5.6K
Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

18.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
20.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K